| 1 | ASCO | 2.11% | |
| 2 | Patients | 1.75% | |
| 3 | Medicina | 1.4% | |
| 4 | Risk | 1.05% | |
| 5 | Status | 1.05% | |
| 6 | Alzheimer’s | 1.05% | |
| 7 | Cancer | 0.7% | |
| 8 | CDC | 0.7% | |
| 9 | Immune | 0.7% | |
| 10 | Checkpoint | 0.7% | |
| 11 | Case | 0.7% | |
| 12 | Study | 0.7% | |
| 13 | Protein | 0.7% | |
| 14 | mCRPC | 0.7% | |
| 15 | New | 0.7% | |
| 16 | Treatment | 0.7% | |
| 17 | May | 0.7% | |
| 18 | Report | 0.7% | |
| 19 | Efficacy | 0.7% | |
| 20 | Gene | 0.7% | |
| 21 | Blood | 0.7% | |
| 22 | Versus | 0.7% | |
| 23 | Tumor | 0.7% | |
| 24 | That | 0.7% | |
| 25 | Disease | 0.7% | |
| 26 | Receptor-Related | 0.35% | |
| 27 | Pfizer | 0.35% | |
| 28 | Presentaran | 0.35% | |
| 29 | Animal | 0.35% | |
| 30 | Septic | 0.35% | |
| 31 | Prostatitis | 0.35% | |
| 32 | Tissue | 0.35% | |
| 33 | Clinical | 0.35% | |
| 34 | NCAA | 0.35% | |
| 35 | Retention | 0.35% | |
| 36 | Caused | 0.35% | |
| 37 | Dog | 0.35% | |
| 38 | Strategies | 0.35% | |
| 39 | Finalist | 0.35% | |
| 40 | Gualeguaychu | 0.35% | |
| 41 | Effectiveness | 0.35% | |
| 42 | IOSPER | 0.35% | |
| 43 | Burden | 0.35% | |
| 44 | Biomarkers | 0.35% | |
| 45 | Durvalumab | 0.35% | |
| 46 | Spacer | 0.35% | |
| 47 | Aura | 0.35% | |
| 48 | Inhibitor | 0.35% | |
| 49 | Contradicted | 0.35% | |
| 50 | Endosteal | 0.35% | |
|
는 분류, 데이터 기준으로 의 기사에서 의 고유명사 데이터를 통해 생성되었습니다.
|
|||